Skip to content
Screener

Exelixis EXEL Total Revenue

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Pfizer logo
PfizerPFE
$15.03B+2.6%
Kura Oncology logo
Kura OncologyKURA
$18.27M+29.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$41M-74.4%

Segments

By product

See full
Gross product revenues$812.78M+9.1%
Discounts and allowances-$239.76M-6.4%
License revenues$59.81M+21.3%
Collaboration$55.67M+15.4%
Collaboration services revenues-$4.53M-80.8%

By geography

See full
U.S.$524.77M
Japan$6.46M

By segment

See full
Reportable Segment$628.69M+10.6%

Other financials

Income statement

See full
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues:
Net product revenues$573,025$520,014$1,128,002$1,033,297
Collaboration revenues55,66548,247111,50090,411
Total revenues628,690568,2611,239,5021,123,708
Operating expenses:
Cost of goods sold20,65719,47040,61038,642
Research and development211,987200,356411,903412,589
Selling, general and administrative147,632134,859287,234272,042

Item 1. Financial Statements.

FAQ

What is Exelixis's total revenue?
Exelixis (EXEL) reported total revenue of $628.69M in Q2 2026.
How has Exelixis's total revenue changed year-over-year?
Exelixis's total revenue increased by 10.6% year-over-year, from $568.26M to $628.69M.
What is the long-term trend for Exelixis's total revenue?
Over 4 years (2021 to 2025), Exelixis's total revenue has grown at a 12.8% compound annual growth rate (CAGR), from $1.43B to $2.32B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Exelixis's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude